A Multicenter Safety and Immunogenicity Window-of-opportunity Phase 1 Interventional Trial Assessing the Combination of IDH1 Vaccine (IDH1-vac) and Vorasidenib in Adult Patients With Recurrent IDH1R132H-mutant Astrocytoma, Grade 2 - 4 (iVOCAL)

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The study aims to investigate the combination of the IDH1R132H peptide vaccine and the dual IDH1/2 inhibitor vorasidenib in patients with recurrent and/or progressive astrocytoma, WHO grade 2,3 and 4. The trial will assess the safety, and immunogenicity of the combined treatment.
Epistemonikos ID: 4ecfa7beae86edd092d235de4bdc76bb88969036
First added on: Oct 17, 2026